Clinical trial · Interventional
Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients
A Pilot Study of Cyclophosphamide/Pegylated Liposomal Doxorubicin/Vincristine/Prednisone (CDOP) Plus Rituximab for Treatment of Elderly Patients With Previously Untreated Non-Hodgkin's Lymphoma
NCT00120198CI-TRIAL-00000982terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): slow accrual
Summary
Brief summary (as posted)
Currently there is no one standard of care for older patients with Non-Hodgkin's Lymphoma (NHL). The study will examine the tolerability and feasibility to the combination of Cyclophosphamide, Pegylated Liposomal Doxorubicin, Vincristine, Prednisone (CDOP) plus Rituximab.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CDOP plus rituximab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the feasibility and tolerability of CDOP plus rituximab in elderly patients with previously untreated NHL.
Secondary outcomes (4)
- measure
- Tumor response
- measure
- duration of response
- measure
- median time to disease progression
- measure
- overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Age 65 years and older; * Diagnosis of Non-Hodgkin's lymphoma where therapy with CHOP plus rituximab is considered; * Previously untreated; * ECOG 0-2 * Adequate renal and hepatic functions; * Cardiac ejection fraction at least 50% by MUGA. No significant cardiac abnormalities by EKG; * Signed informed consent Exclusion Criteria: * CNS involvement by lymphoma; * Hypersensitivity to study drugs; * Active infection; * Prior treatment with monoclonal antibodies for cancer; * History of cardiac disease with New York Heart Association Class II or greater or clinical evidence of congestive heart failure
References
Publications (0)
Data not yet available
No reference posted for this study.